
Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18374
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gaikwad, Anil Bhanudas | - |
dc.date.accessioned | 2025-03-15T07:00:16Z | - |
dc.date.available | 2025-03-15T07:00:16Z | - |
dc.date.issued | 2025-01 | - |
dc.identifier.uri | https://academic.oup.com/jpp/advance-article-abstract/doi/10.1093/jpp/rgaf002/7964751?login=true | - |
dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18374 | - |
dc.description.abstract | Chronic kidney disease (CKD) is a serious health issue with rising morbidity and mortality rates. Despite advances in understanding its pathophysiology, effective therapeutic options are limited, necessitating innovative treatment approaches. Also, current frontline treatments that are available against CKD are not uniformly effective and often come with significant side effects. Therefore, identifying new therapeutic targets or improving existing treatments for CKD is crucial. Drug repurposing is a promising strategy in the drug discovery process that involves screening existing approved drugs for new therapeutic applications. | en_US |
dc.language.iso | en | en_US |
dc.publisher | OUP | en_US |
dc.subject | Pharmacy | en_US |
dc.subject | Chronic kidney disease (CKD) | en_US |
dc.subject | Drug repurposing | en_US |
dc.subject | Inodilators | en_US |
dc.subject | Endothelin receptor antagonists | en_US |
dc.subject | Bisphosphonates | en_US |
dc.title | Repurposing the familiar: future treatment options against chronic kidney disease | en_US |
dc.type | Article | en_US |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.